Solórzano-Santos F, Quezada-Herrera A, Fuentes-Pacheco Y, Labra-Zamora MG, Rodríguez-Coello G, Aguirre-Morales CE, Izelo-Flores D, Muñoz-Hernández O, Miranda-Novales MG

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 283-290
Archivo PDF: 412.84 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Cohen C, King A, Lin CP, Friedman GK, Monroe K, Kutny M, et al. Protocol for reducing time to antibiotics in pediatric patients presenting to an emergency department with fever and neutropenia: efficacy and barriers. Pediatr Emerg Care. 2016; 32:739-45.

2. Lee JH, Kim SK, Kim SK, Han SB, Lee JW, Lee DG, et al. Increase in antibiotic-resistant gram-negative bacterial infections in febrile neutropenic children. Infect Chemother. 2016;48:181-9.

3. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017; 35:2082-94.

4. Kim HS, Park BK, Kim SK, Han SB, Lee JW, Lee DG, et al. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study. BMC Infect Dis. 2017;17:500.

5. Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H. The effect of critical illness on drug distribution. Curr Pharm Biotechnol. 2011;12:2030-6.

6. Cies JJ, Jain J, Kuti JL. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia. Pediatr Blood Cancer. 2015;62:477-82.

7. Patel GW, Patel N, Lat A, Trombley K, Enbawe S, Manor K, et al. Outcomes of extended infusion piperacillin/tazobactam for documented gram-negative infections. Diagn Microbiol Infect Dis. 2009;64:236-40.

8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10.

9. Tamura K, Akiyama N, Kanda Y, Saito M. Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan. J Infect Chemother. 2015;21:654-62.

10. Yang H, Cui X, Ma Z, Liu L. Evaluation outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. J Pharm Pharm Sci. 2016;19: 274-89.

11. Bao H, Lv Y, Wang D, Xue J, Yan Z. Clinical outcomes of extended versus intermittent administration of piperacillin/tazo- bactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial. Eur J Clin Microbiol Infect Dis. 2017; 36:459-66.

12. Fan SY, Shum HP, Cheng WY, Chan YH, Leung SM, Yan WW, et al. Clinical outcomes of extended versus intermittent infusion of piperacillin/tazobactam in critically ill patients: a prospective clinical trial. Pharmacotherapy. 2017;37:109-19.

13. Nichols KR, Knoderer CA, Cox EG, Kays MB. System-wide implementation of the use of an extended-infusion piperacillin/tazobactam dosing strategy: feasibility of utilization from a children’s hospital perspective. Clin Ther. 2012;34:1459-65.

14. Knoderer CA, Karmire LC, Andricopulos KL, Nichols KR. Extended infusion of piperacillin/tazobactam in children. J Pediatr Pharmacol Ther. 2017;22:212-7.

15. Ram R, Halavy Y, Amit O, Paran Y, Katchman E, Yachini B, et al. Extended vs bolus infusion of broad-spectrum β-lactams for febrile neutropenia: an unblinded, randomized trial. Clin Infect Dis. 2018;67:1153-60.

16. Yang H, Zhang C, Zhou Q, Wang Y, Chen L. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. PLoS One. 2015;10: e0116769.

17. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013; 56:272-82.

18. Brunetti L, Poustchi S, Cunningham D, Toscani M, Nguyen J, Lim J, et al. Clinical and economic impact of empirical extended-infusion piperacillin-tazobactam in a community medical center. Ann Pharmacother. 2015;49:754-60.

19. Al-Tawfiq JA, Hinedi K, Khairallah H, Saadeh B, Abbasi S, Noureen M, et al. Epidemiology and source of infection in patients with febrile neutropenia: a ten-year longitudinal study. J Infect Public Health. 2019;12:364-6.

20. Horita N, Shibata Y, Watanabe H, Namkoong H, Kaneko T. Comparison of antipseudomonal β-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microbiol Infect. 2017;23:723-9.

21. Santolaya ME, Alvarez AM, Acuña M, Avilés CL, Salgado C, Tordecilla J, et al. Efficacy and safety of withholding antimicrobial treatment in children with cancer, fever and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial. Clin Microbiol Infect. 2017;23:173-8.

22. De la Maza V, Simian D, Castro M, Torres JP, Lucero Y, Sepúlveda F, et al. Administration time for the first dose of antimicrobials in episodes of fever and neutropenia in children with cancer. Pediatr Infect Dis J. 2015;34:1069-73.

23. Maddox ML, DeBoer EC, Hammerquist RJ. Administration of extended infusion piperacillin-tazobactam with the use of smart pump technology. Hosp Pharm. 2014;49:444-8.

24. Wrenn RH, Cluck D, Kennedy L, Ohl C, Williamson JC. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia. J Oncol Pharm Pract. 2018;24:170-5.